Evolving etiologies of liver transplantation: a trend analysis from 2020 to 2024 at the main center of Iran
Gastroenterology and Hepatology from Bed to Bench,
Vol. 18 No. 1 (2025),
4 January 2025
https://doi.org/10.22037/ghfbb.v18i1.3035
Abstract
Aim: This study aimed to analyze trends in the etiologies of liver transplants at Abu Ali Sina Hospital, Shiraz, Iran, from 2020 to 2024.
Background: Liver transplantation (LT) is a crucial treatment for end-stage liver disease (ESLD). Over time, the etiologies leading to LT have evolved due to changes in disease prevalence, advancements in medical treatments, and public health interventions.
Methods: Etiologies of LT were categorized into nine groups: acute liver failure, autoimmune disorders, alcoholic steatohepatitis, liver cancer, vascular, metabolic dysfunction-associated steatohepatitis (MASH), viral hepatitis, metabolic disorders, and others. Trend analysis was performed using Python 3.12 programming language with appropriate libraries.
Results: A total of 1579 patients, 59.9% male with a mean age of 45.12 years (SD: 13.52), were analyzed. Autoimmune disorders emerged as the leading cause of LT, increasing from 32.2% in 2020 to 40.6% in 2024 (p-trend = 0.039). Viral hepatitis cases decreased significantly from 18.1% to 3.0% (p-trend = 0.033). Liver cancer became the third leading cause in 2021, replacing viral hepatitis, while MASH consistently remained the second leading cause.
Conclusion: The significant shifts in LT etiologies underscore the success of public health interventions in reducing the burden of viral-related ESLD. Additionally, the findings highlight the need for ongoing research into the prevention, early diagnosis, and management of autoimmune liver diseases, MASH, and liver cancer. These findings provide critical insights for clinicians and policymakers to enhance liver disease management and allocate resources effectively.
- Biliary Tract Diseases
- Autoimmune Hepatitis
- Hepatitis B
- Hepatitis C
- Non-alcoholic Fatty Liver Disease
- Hepatocellular Carcinoma
- Cholangiocarcinoma
How to Cite
References
Malek-hosseini SA, Salahi H, Lahsaee M, Bahador A, Lankarani MB, Imanieh MH, et al. Initial experience with liver transplantation in Iran. Transplant Proc 2003;35:375-6.
Malek-Hosseini SA, Habibzadeh F, Nikeghbalian S. Shiraz Organ Transplant Center: The Largest Liver Transplant Center in the World. Transplantation 2019;103.
Malek-Hosseini SA, Jafarian A, Nikeghbalian S, Poustchi H, Lankarani KB, Nasiri Toosi M, et al. Liver Transplantation Status in Iran: A multi-center report on the main transplant indicators and survival rates. Arch Iran Med 2018;21:275-82.
Malek Hosseini SA, Nikeghbalian S, Salahi H, Kazemi K, Shemsaeifar A, Bahador A, et al. Evolution of Liver transplantation program in Shiraz, Iran. Hepat Mon 2017;17:60745.
Akarsu M, Dolu S, Harputluoglu M, Yilmaz S, Akyildiz M, Gencdal G, et al. Changing trends in the etiology of liver transplantation in Turkiye: A multicenter study. Hepatol Forum 2024;5:3-6.
Battistella S, Grasso M, Catanzaro E, D'Arcangelo F, Corrà G, Germani G, et al. Evolution of liver transplantation indications: expanding horizons. Medicina 2024;60.
Wong RJ, Singal AK. Trends in liver disease etiology among adults awaiting liver transplantation in the United States, 2014-2019. JAMA Netw Open 2020;3:1920294.
Hahn JW, Yang HR, Moon JS, Chang JY, Lee K, Kim GA, et al. Global incidence and prevalence of autoimmune hepatitis, 1970-2022: a systematic review and meta-analysis. EClinicalMedicine 2023;65:102280.
Miao L, Targher G, Byrne CD, Cao Y-Y, Zheng M-H. Current status and future trends of the global burden of MASLD. Trends Endocrinol Metab 2024;35:697-707.
Hajarizadeh B, Razavi-Shearer D, Merat S, Alavian SM, Malekzadeh R, Razavi H. Liver disease burden of hepatitis c virus infection in iran and the potential impact of various treatment strategies on the disease burden. Hepat Mon 2016;16:37234.
Sepanlou SG, Malekzadeh F, Naghavi M, Forouzanfar MH, Shahraz S, Moradi-Lakeh M, et al. Trend of gastrointestinal and liver diseases in Iran: results of the global burden of disease study, 2010. Middle East J Dig Dis 2015;7:121-37.
Malekzadeh MM, Vahedi H, Gohari K, Mehdipour P, Sepanlou SG, Ebrahimi Daryani N, et al. Emerging epidemic of inflammatory bowel disease in a middle income country: a nation-wide study from Iran. Arch Iran Med 2016;19:2-15.
Yadav V, Irfan R, Safdar S, Sunkara V, Ekhator C, Pendyala PR, et al. Advances in understanding and managing autoimmune hepatitis: a narrative review. Cureus 2023;15:43973.
Lee WM. Etiologies of acute liver failure. Semin Liver Dis 2008;28:142-52.
Alavian SM, Fallahian F, Lankarani KB. The changing epidemiology of viral hepatitis B in Iran. J Gastrointestin Liver Dis 2007;16:403-6.
Rezaei N, Asadi-Lari M, Sheidaei A, Gohari K, Parsaeian M, Khademioureh S, et al. Epidemiology of hepatitis B in Iran from 2000 to 2016: a systematic review and meta-regression analysis. Arch Iran Med 2020;23:189-96.
Rumgay H, Arnold M, Ferlay J, Lesi O, Cabasag CJ, Vignat J, et al. Global burden of primary liver cancer in 2020 and predictions to 2040. J Hepatol 2022;77:1598-606.
Yang JD, Heimbach JK. New advances in the diagnosis and management of hepatocellular carcinoma. Br Med J 2020;371:3544.
Lonardo A, Leoni S, Alswat KA, Fouad Y. History of nonalcoholic fatty liver disease. Int J Mol Sci 2020;21.
Noureddin M, Vipani A, Bresee C, Todo T, Kim IK, Alkhouri N, et al. NASH leading cause of liver transplant in women: updated analysis of indications for liver transplant and ethnic and gender variances. Am J Gastroenterol 2018;113:1649-59.
Sadler EM, Mehta N, Bhat M, Ghanekar A, Greig PD, Grant DR, et al. Liver transplantation for NASH-related hepatocellular carcinoma versus non-NASH etiologies of hepatocellular carcinoma. Transplantation 2018;102.
Jamalinia M, Zare F, Lankarani KB. Systematic review and meta-analysis: Association between liver fibrosis and subclinical atherosclerosis in nonalcoholic fatty liver disease. Aliment Pharmacol Ther 2023;58:384-94.
Jamalinia M, Zare F, Noorizadeh K, Bagheri Lankarani K. Systematic review with meta-analysis: Steatosis severity and subclinical atherosclerosis in metabolic dysfunction-associated steatotic liver disease. Aliment Pharmacol Ther 2024;59:445-58.
Jamalinia M, Lonardo A. Perspective article: determinants and assessment of cardiovascular risk in steatotic liver disease owing to metabolic dysfunction-addressing the challenge. Metab Target Organ Damage 2024;4:23.
- Abstract Viewed: 659 times
- PDF Downloaded: 362 times